v3.26.1
SEGMENT - Schedule of Disaggregated Expense Information Included in the Consolidated Statements of Comprehensive Loss (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Segment research and development expenses:      
Segment administrative expenses $ 26,416 $ 8,309  
Cash and cash equivalents 190,637   $ 210,632
Segment      
Segment research and development expenses:      
Direct clinical development expenses 7,979    
Employee-related expenses 4,748    
Other research and development expenses 1,602    
Segment administrative expenses 26,416    
Other segment items (2,877)    
Segment net loss (37,868)    
Cash and cash equivalents 190,637    
Segment | GIVA      
Segment research and development expenses:      
Direct clinical development expenses 7,925    
Segment | Other oncology      
Segment research and development expenses:      
Direct clinical development expenses 0    
Segment | NovaBridge      
Segment research and development expenses:      
Direct clinical development expenses 7,925 189  
Employee-related expenses 3,408 2,775  
Other research and development expenses 1,040 1,107  
Segment administrative expenses 23,135 8,309  
Other segment items (2,832) (3,726)  
Segment net loss (32,676) (8,654)  
Cash and cash equivalents 165,464 165,404  
Segment | NovaBridge | GIVA      
Segment research and development expenses:      
Direct clinical development expenses 7,925 202  
Segment | NovaBridge | Other oncology      
Segment research and development expenses:      
Direct clinical development expenses 0 $ (13)  
Segment | Visara      
Segment research and development expenses:      
Direct clinical development expenses 54    
Employee-related expenses 1,340    
Other research and development expenses 562    
Segment administrative expenses 3,281    
Other segment items (45)    
Segment net loss (5,192)    
Cash and cash equivalents $ 25,173